Circulating carcinoembryonic antigen in pancreatic carcinoma
- PMID: 709516
- DOI: 10.1002/1097-0142(197809)42:3+<1468::aid-cncr2820420816>3.0.co;2-i
Circulating carcinoembryonic antigen in pancreatic carcinoma
Abstract
Circulating CEA levels were determined in 102 patients wtih histologically proven pancreatic carcinoma and 26 patients with chronic pancreatitis. In the group with pancreatic carcinoma eleven patients had resectable tumors, the mean CEA in the nonjaundiced patients was 10 +/- 5 ng/ml while the mean value in jaundiced patients in this group was 27 +/- 40. Thirty-four patients with nonmetastatic locally unresectable disease had a mean serum CEA of 25 +/- 52 with a range of 1 to 250 ng/ml. Twenty-one percent had values of 5 ng/ml or less. The mean value in 57 patients with metastatic disease was 97 +/- 194 with a range of 0.05 to 1000 ng/ml and 19 percent had values of 5 ng/ml or less. Survival of patients with locally unresectable or metastatic carcinoma was significantly longer in those patients who had a normal CEA at the time of diagnosis. Circulating CEA in the metastatic group was much lower in patients with nonhepatic metastases as well as in those with well differentiated adenocarcinoma histology. Twenty-three patients with chronic pancreatitis and normal serum bilirubin had a mean CEA value of 5.3 +/- 4 ng/ml with 65% of values being 5 ng/ml or less but the CEA ranged from 4.6 to 27 in three who were jaundiced.
Similar articles
-
Initial levels of CEA and their rate of change in pancreatic carcinoma following surgery chemotherapy and radiation therapy.Cancer. 1978 Sep;42(3 Suppl):1472-6. doi: 10.1002/1097-0142(197809)42:3+<1472::aid-cncr2820420817>3.0.co;2-w. Cancer. 1978. PMID: 709517
-
Carcinoembryonic antigen (CEA) activity in pancreatic juice of patients with pancreatic carcinoma and pancreatitis.Cancer. 1976 Dec;38(6):2457-61. doi: 10.1002/1097-0142(197612)38:6<2457::aid-cncr2820380634>3.0.co;2-3. Cancer. 1976. PMID: 1000475
-
[The value of poly-C-specific serum ribonuclease and CEA in the diagnosis of pancreatic carcinoma (author's transl)].Klin Wochenschr. 1981 Nov 2;59(21):1201-7. doi: 10.1007/BF01721215. Klin Wochenschr. 1981. PMID: 7311390 German.
-
Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology.PLoS One. 2016 Jan 25;11(1):e0147214. doi: 10.1371/journal.pone.0147214. eCollection 2016. PLoS One. 2016. PMID: 26808421 Free PMC article.
-
Marked elevation of plasma carcinoembryonic antigen and stomach carcinoma.Cancer. 1996 May 15;77(10):1991-7. doi: 10.1002/(SICI)1097-0142(19960515)77:10<1991::AID-CNCR5>3.0.CO;2-K. Cancer. 1996. PMID: 8640661 Review.
Cited by
-
Monoclonal antibodies against CEA-related components discriminate between pancreatic duct type carcinomas and nonneoplastic duct lesions as well as nonduct type neoplasias.Virchows Arch A Pathol Anat Histopathol. 1986;408(4):361-74. doi: 10.1007/BF00707694. Virchows Arch A Pathol Anat Histopathol. 1986. PMID: 3004013
-
Tissue polypeptide antigen (TPA) in pancreatic cancer diagnosis.Br J Cancer. 1985 Nov;52(5):801-3. doi: 10.1038/bjc.1985.262. Br J Cancer. 1985. PMID: 4063154 Free PMC article. No abstract available.
-
The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer.Br J Cancer. 1994 Mar;69(3):515-9. doi: 10.1038/bjc.1994.93. Br J Cancer. 1994. PMID: 7510116 Free PMC article.
-
The Past, Present, and Future of Biomarkers for the Early Diagnosis of Pancreatic Cancer.Biomedicines. 2024 Dec 13;12(12):2840. doi: 10.3390/biomedicines12122840. Biomedicines. 2024. PMID: 39767746 Free PMC article. Review.
-
CAM 17.1--a new diagnostic marker in pancreatic cancer.Br J Cancer. 1996 Dec;74(12):1997-2002. doi: 10.1038/bjc.1996.666. Br J Cancer. 1996. PMID: 8980403 Free PMC article.